Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Yale J Biol Med. 2010 Dec;83(4):209-15.
Approximately 2 million people die of tuberculosis (TB) each year. The current vaccine, Bacille Calmette-Guérin (BCG), albeit widely employed, does not protect against adult pulmonary disease, and new vaccines are urgently needed to reduce the incidence of TB worldwide. New insights into the cellular and molecular mechanisms that underlie the interactions between Mycobacterium tuberculosis and its host have been exploited to develop novel vaccine candidates that recently have entered clinical trials. This review provides a brief overview of different approaches toward a new vaccination strategy and summarizes major challenges for the next decade.
每年约有 200 万人死于结核病（TB）。目前使用的卡介苗（BCG）疫苗虽然应用广泛，但不能预防成人肺部疾病，因此迫切需要新的疫苗来降低全球结核病的发病率。目前，人们利用对结核分枝杆菌与其宿主相互作用的细胞和分子机制的新认识，开发了新的疫苗候选物，这些候选物最近已进入临床试验。本文简要概述了新的疫苗接种策略的不同方法，并总结了未来十年的主要挑战。
